KW-0761 (mogamulizumab)
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-Cell Lymphoma
Conditions
Peripheral T-Cell Lymphoma
Trial Timeline
Apr 1, 2012 → May 1, 2015
NCT ID
NCT01611142About KW-0761 (mogamulizumab)
KW-0761 (mogamulizumab) is a phase 2 stage product being developed by Kyowa Kirin for Peripheral T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01611142. Target conditions include Peripheral T-Cell Lymphoma.
What happened to similar drugs?
8 of 20 similar drugs in Peripheral T-Cell Lymphoma were approved
Approved (8) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01611142 | Phase 2 | Completed |
Competing Products
20 competing products in Peripheral T-Cell Lymphoma